11.29
-0.12(-1.05%)
Currency In USD
| Previous Close | 11.41 |
| Open | 11.35 |
| Day High | 11.49 |
| Day Low | 10.95 |
| 52-Week High | 13.82 |
| 52-Week Low | 4.93 |
| Volume | 183,171 |
| Average Volume | 219,705 |
| Market Cap | 431.5M |
| PE | -4.39 |
| EPS | -2.57 |
| Moving Average 50 Days | 10.77 |
| Moving Average 200 Days | 7.86 |
| Change | -0.12 |
If you invested $1000 in Entrada Therapeutics, Inc. (TRDA) since IPO date, it would be worth $471.4 as of February 21, 2026 at a share price of $11.29. Whereas If you bought $1000 worth of Entrada Therapeutics, Inc. (TRDA) shares 3 years ago, it would be worth $989.48 as of February 21, 2026 at a share price of $11.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
GlobeNewswire Inc.
Feb 17, 2026 12:00 PM GMT
-- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201 -- -- Company on track to report ELEVATE-44-201 Cohort 1 data in Q2 2026, with Cohort 2 data by end of year -- BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- En
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 – -- Expects to initiate global Phase 1/2 MAD clinical study of ENTR-601-50 by the end of 2026 and to submit
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 17, 2025 12:00 PM GMT
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, Ja